This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Using data from the Italian Longitudinal Study on Aging (ILSA), Di Carlo et al. reported a higher (16.1%) prevalence of mild cognitive impairment (MCI) than we reported in this same elderly population (3.2%).1
An explanation for this difference may be the more liberal criterion for MCI (subjects not scoring >1 SD below the mean of an age- and education-adjusted mean on the Mini-Mental State Examination [MMSE]) than used by studies using more conventional criteria.2 Using more conventional criteria (subjects not scoring >1.5 SDs below mean age- and education-adjusted on the MMSE and scoring >10th percentile below age- and education-adjusted on Babcock Story Recall Test [assessing episodic memory]) in exactly the same cohort, we found a prevalence rate of 3.2% for MCI.3
This diagnosis did not exclude subjects with mild impairment on activities of daily living and instrumental activities of daily living and individuals affected by numerous comorbidities not influencing global cognitive functions. Therefore, they may be well represented by aMCI.3 Prevalence estimates of amnestic variants of MCI in other worldwide population-based studies are consistent with those reported in our study: 3% in France (Eugeria Longitudinal Study of Cognitive Aging); 3.1% in Germany (Leipzig Longitudinal Study of the Aged); 3.02% in Canada (Canadian Study of Health and Aging); and 3.2% in the United States (MoVIES study).2 Two exceptions were 5% reported in an urban community in northern Manhattan,4 closer to the MCI prevalence rate reported in our study rather than those estimated in the study …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker